INTECH BIOPHARM LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of inhalants and related products. The Company's main products include respiratory drugs, the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. The Company distributes its products in domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-28	NT$26.55	+0.95%	31,783
26-10-27	NT$26.30	-2.23%	75,681
26-10-22	NT$26.90	-0.74%	41,167
26-10-21	NT$27.10	-2.69%	80,784
26-10-20	NT$27.85	-2.62%	133,832

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-28			5-day change	1st Jan Change
26.55 ^TWD	+0.95%		-2.03%	-7.73%

08-11	Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.93B 90.27M 80.99M 74.88M 67.81M 127M 8.6B 128M 895M 357M 4.5B 339M 332M 14.28B	P/E 2024	-9.84x	P/E 2025	-6.93x
Enterprise Value	3.9B 120M 108M 99.78M 90.37M 169M 11.46B 171M 1.19B 475M 6B 451M 442M 19.03B	EV / Sales 2024	121x	EV / Sales 2025	36x
Free-Float	46.43%	Yield 2024 *	-	Yield 2025	-

08-11	Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-16	Intech Biopharm Ltd. Announces Change in Corporate Representative Director Appointed by Jet United Investment Limited, Effective January 17, 2026	CI
12-26	Intech Biopharm Ltd. Signs Exclusive Licensing Agreement	CI
11-11	Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-07	Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	Intech Biopharm Corporation Announces Executive Changes, Effective from June 12, 2025	CI
25-06-03	Intech Biopharm Ltd. Announces Directorate Change Due to Passing Away of Chiu, Hui-Lan on June 3, 2025	CI
25-05-11	Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-06	Intech Biopharm Ltd. Signs Supplemental Agreement for the SYN010 Product with Haisco Pharmaceutical Group	CI
25-03-12	Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-13	Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

1 day	+0.95%
1 week	-2.03%
Current month	+8.59%
1 month	+11.55%
3 months	+6.64%
6 months	-9.01%
Current year	-7.73%

Intech Biopharm Corporation Stock

Stocks

6461

TW0006461007

Pharmaceuticals

Valuation: Intech Biopharm Corporation

Chart: Intech Biopharm Corporation

Latest news: Intech Biopharm Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Intech Biopharm Corporation

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

1 week	25.9	27.5
1 month	23.75	29.8
Current year	23.3	42.44
1 year	22.79	42.44
3 years	22.79	55.93
5 years	22.79	75.58
10 years	18.51	94.57

Manager	Title	Age	Since
Wei Hsiu Wu CEO	Chief Executive Officer	-	2017-07-10
Chien Yao Yang DFI	Director of Finance/CFO	-	2013-07-22
Yan-Qin Zhao CTO	Chief Tech/Sci/R&D Officer	-	2019-12-26

Director	Title	Age	Since
Chih Hui Lin CHM	Chairman	-	2010-10-27
Te Chien Chou BRD	Director/Board Member	68	2014-04-01
Te Chuan Fan BRD	Director/Board Member	43	2015-06-10

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTECH BIOPHARM CORPORATION	+0.95%	-2.03%	-2.24%	-36.47%	89.48M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,143B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	647B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	506B
ROCHE HOLDING AG	-0.05%	+1.73%	+52.74%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	350B
NOVARTIS AG	+0.34%	+1.84%	+30.70%	+54.27%	293B
ASTRAZENECA PLC	-0.45%	+1.19%	+2.89%	+26.08%	265B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	242B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+0.23%	+0.88%	+36.35%	+65.12%	402.76B
Weighted average by Cap.	+0.25%	+1.58%	+44.50%	+89.01%

	2024	2025
Net sales	39.78M 1.23M 1.1M 1.02M 921K 1.72M 117M 1.74M 12.16M 4.84M 61.09M 4.6M 4.5M 194M	108M 3.31M 2.97M 2.75M 2.49M 4.65M 316M 4.71M 32.86M 13.09M 165M 12.43M 12.17M 524M
Net income	-368M -11.35M -10.18M -9.41M -8.52M -15.93M -1.08B -16.12M -113M -44.82M -566M -42.58M -41.68M -1.8B	-389M -11.99M -10.76M -9.94M -9.01M -16.83M -1.14B -17.03M -119M -47.36M -597M -44.99M -44.04M -1.9B
Net Debt	1.18B 36.3M 32.56M 30.11M 27.27M 50.94M 3.46B 51.56M 360M 143M 1.81B 136M 133M 5.74B	974M 30.03M 26.94M 24.91M 22.56M 42.14M 2.86B 42.65M 298M 119M 1.5B 113M 110M 4.75B